Bispecific Therapies in Relapsed/Refractory Multiple Myeloma
Panelists discuss how bispecific antibodies targeting B-cell maturation agent, GPRC5D, and FcRH5 are transforming relapsed/refractory multiple myeloma treatment (R/R MM) with promising efficacy, manageable safety profiles, and convenient off-the-shelf administration.
EP: 1.Brief Overview of Therapeutic Landscape for R/R MM
EP: 2.Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma
EP: 3.MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab
EP: 4.Elranatamab Dosing Strategies: Implications for Community Practice
EP: 5.Navigating Post–CAR T Progression: Therapy Selection and Targeting
EP: 6.Bispecific Therapies in Relapsed/Refractory Multiple Myeloma
EP: 7.ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma
Video content above is prompted by the following:
- What are some data updates at ASH 2024 that you are excited about?
- Before we close, I would like each of you to share some key takeaways and clinical pearls on the treatment of patients with R/R MM in the era of bispecifics for your community colleagues.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
